B

명인제약

317450KOSPI의약품 제조업

63.9 / 100

Reference Date: 2026-07-24

Financial Score32.0 / 40
News Sentiment15.9 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health and ROE significantly exceeds the industry average is also solid. Roughly flat over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Myungin Pharmaceutical specializes in developing and producing CNS-focused specialty pharmaceuticals, including treatments for stroke, Parkinson's disease, and depression, securing the top position in the domestic market according to IQVIA 2025 Q4 data. Leveraging its full-process production capabilities from raw material synthesis to finished products, the company expands partnerships with global pharmaceutical firms and maintains a strong market presence in OTC products as well.

Number of Employees

532people

Average Salary

78.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
6.32Industry Average 11.236.5Point

Lower than industry avg (good)

PBR
0.78Industry Average 0.814.0Point

In line with industry avg

ROE
12.28Industry Average 4.017.0Point

3.1x industry avg (excellent)

Debt Ratio
0.14Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 6.5 / 10 points
Revenue Growth Rate
1.5 / 3

Operating Profit Growth Rate
1.5 / 3

ROE Trend
3.5 / 4

Detailed News Sentiment

4 totalPositive 1Neutral 0Negative 3Average Sentiment Score 63.8

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 42,450Won52-week high 121,90052-week low 39,800
1-month return3.0Point

1m 0.35% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0